
Kura Oncology, Inc.
KURA
KURA: Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
moreShow KURA Financials
Recent trades of KURA by members of U.S. Congress
Politician | Type | Traded |
---|---|---|
Christopher L. Jacobs House / R | Purchase $1,001 - $15,000 | Dec. 12, 2022 |
Recently reported changes by institutional investors
Quarterly net insider trading by KURA's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on KURA's company Twitter account
Number of mentions of KURA in WallStreetBets Daily Discussion
Recent insights relating to KURA
Recent picks made for KURA stock on CNBC
ETFs with the largest estimated holdings in KURA
Flights by private jets registered to KURA